000			03495nam a22004577a 4500
008			240807s20242024 xxu||||| |||| 00| 0 eng d
022			_a2057-3804
024			_a10.1186/s40959-024-00234-0 [pii]
024			_aPMC11100143 [pmc]
040			_aOvid MEDLINE(R)
099			_a38760863
245			_aImmune checkpoint inhibitors and pericardial disease: a systematic review.
251			_aCardio-Oncology. 10(1):29, 2024 May 17.
252			_aCardiooncology. 10(1):29, 2024 May 17.
253			_aCardio-oncology (London, England)
260			_c2024
260			_fFY2024
260			_p2024 May 17
265			_sepublish
265			_tPubMed-not-MEDLINE
266			_d2024-08-07
266			_z2024/05/17 23:42
520			_aDISCUSSION: This study provides the most comprehensive analysis of ICI-mediated pericardial disease to date. Patients affected were most commonly male with lung cancer treated with either Nivolumab or Pembrolizumab. Diagnosis may be challenging in the setting of occult presentation with normal EKG and physical exam as well as delayed onset from therapy initiation. ICI-associated pericardial disease demonstrates high morbidity and mortality, as evidenced by a majority of patients requiring pericardiocentesis. Copyright © 2024. The Author(s).
520			_aINTRODUCTION: Despite the growing use of immune checkpoint inhibitors (ICI) in cancer treatment, data regarding ICI-associated pericardial disease are primarily derived from case reports and case series. ICI related pericardial disease can be difficult to diagnose and is associated with significant morbidity. We conducted a systematic review to further characterize the epidemiology, clinical presentation, and outcomes of this patient population.
520			_aMETHODS: A search of four databases resulted in 31 studies meeting inclusion criteria. Patients > 18 years old who presented with ICI mediated pericardial disease were included. Intervention was medical + surgical therapy and outcomes were development of cardiac tamponade, morbidity, and mortality.
520			_aRESULTS: Thirty- eight patients across 31 cases were included. Patients were majority male (72%) with a median age of 63. Common symptoms included dyspnea (59%) and chest pain (32%), with 41% presenting with cardiac tamponade. Lung cancer (81%) was the most prevalent, and nivolumab (61%) and pembrolizumab (34%) were the most used ICIs. Pericardiocentesis was performed in 68% of patients, and 92% experienced symptom improvement upon ICI cessation. Overall mortality was 16%.
546			_aEnglish
650			_zAutomated
656			_aInternal Medicine Residency
656			_aMedStar Georgetown University Hospital/MedStar Washington Hospital Center
657			_aJournal Article
700			_aKumar, Ashwin _bMGUH _cInternal Medicine Residency _dDO
700			_aLi, Jason _bMGUH _cInternal Medicine Residency _dMD
700			_aMcGowan, Kevin _bMGUH _cInternal Medicine Residency _dMD
700			_aMudra, Sarah _bMGUH _cInternal Medicine Residency _dMD
700			_aNjus, Meredith _bMGUH _cInternal Medicine Residency _dMD
700			_aRayes, Danny _bMGUH _cInternal Medicine Residency _dMD
790			_aMudra SE, Rayes DL, Agrawal A, Kumar AK, Li JZ, Njus M, McGowan K, Kalam KA, Charalampous C, Schleicher M, Majid M, Syed A, Yesilyaprak A, Klein AL
856			_uhttps://dx.doi.org/10.1186/s40959-024-00234-0 _zhttps://dx.doi.org/10.1186/s40959-024-00234-0
942			_cART _dArticle
999			_c14499 _d14499